<DOC>
	<DOCNO>NCT03086395</DOCNO>
	<brief_summary>Patients post transplant lymphoproliferative disorder ( PTLD ) treat least one type chemotherapy , whose lymphoma respond come back previous treatment ask participate study . This clinical trial use drug call Obinutuzumab . The Food Drug Administration ( FDA ) approve Obinutuzumab sale United States certain disease . Obinutuzumab still study clinical trial learn side effect whether effective disease condition study . Obinutuzumab consider investigational drug study Obinutuzumab ( GA101 ) antibody direct cluster differentiation antigen 20 ( CD20 ) . Antibodies protein part immune system target cancer cell . Obinutuzumab stick target call CD20 . CD20 important molecule cancer cell ( include non-Hodgkin lymphoma ) normal cell immune system . This study do test study drug effect post transplant lymphoproliferative disorder see lymphoma respond study drug .</brief_summary>
	<brief_title>Single Agent Obinutuzumab Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder ( PTLD )</brief_title>
	<detailed_description>Primary Objective : • To determine overall response rate obinutuzumab relapsed/refractory post-transplant lymphoproliferative disorder ( PTLD ) solid organ transplant ( SOT ) bone marrow transplant ( BMT ) patient Secondary Objectives : - Complete remission ( CR ) rate - Duration response ( DOR ) - Progression free survival ( PFS ) - Overall survival ( OS ) - Time treatment failure ( TTF ) - Safety tolerability obinutuzumab Patient Population : Relapsed refractory post-transplant lymphoproliferative disorder ( PTLD ) patient receive least one prior therapy Study Design : Phase II study single agent obinutuzumab relapsed/refractory ( RR ) post-transplant lymphoproliferative disorder ( PTLD ) SOT BMT patient</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Histologically cytologically confirm relapsed/refractory posttransplant lymphoproliferative disorder Relapsed/refractory disease least 1 prior chemotherapy regimen Measurable disease ≥1.5 cm Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . ECOG 3 permitted decline performance status attribute lymphoma Able sign consent form Adequate organ function bilirubin ≤1.5 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 time ULN ≤5 time ULN patient document hepatic involvement lymphoma serum creatinine clearance &gt; 50 ml/min absolute neutrophil count ( ANC ) ≥500/μL ( unless document bone marrow involvement lymphoma ) hemoglobin &gt; 8 gm/dl platelet count ≥50,000/μL ( unless document bone marrow involvement lymphoma ) Prior treatment obinutuzumab Pregnancy breast feed woman Current active malignancy PTLD , require active treatment Presence central nervous system ( CNS ) involvement HIV positive patient Myocardial infarction within past 6 month Patients follow medical condition could affect participation study : active acute chronic uncontrolled infection liver disease include history viral hepatitis B C , evidence cirrhosis , chronic active persistent hepatitis know history HIV symptomatic cardiac disease , include congestive heart failure , coronary artery disease , arrhythmias Current therapy chemotherapy investigational agent within 4 week start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
</DOC>